PTC Therapeutics (NASDAQ: PTCT) reported Q4 EPS of ($2.06), $2.55 worse than the analyst estimate of $0.49. Revenue for the quarter came in at $307.1 million versus the consensus estimate of $316.48 million.

GUIDANCE:

PTC Therapeutics sees Q1 2024 revenue of $600-680 million.

• PTC anticipates total revenues for full year 2024 to be between $600 million and $680 million.
• PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between $740 million and $835 million.
• PTC anticipates Non-GAAP R&D and SG&A expense for full year 2024 to be between $660 million and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.
• PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expense.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.